Interstitial pneumonitis following sequential administration of programmed death-1/programmed death-ligand1 inhibitors and epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer: A matched‐pair cohort study using a nationwide inpatient database

It is unclear whether the sequential administration of programmed death (PD)-1/programmed death-ligand 1 (PD-L1) inhibitors and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is associated with the development of severe interstitial pneumonitis (IP).